Page last updated: 2024-09-04

pomalidomide and Lymphoma, Primary Effusion

pomalidomide has been researched along with Lymphoma, Primary Effusion in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's2 (50.00)2.80

Authors

AuthorsStudies
Astter, Y; Davis, DA; Lurain, K; Ramaswami, R; Shrestha, P; Wang, HW; Yarchoan, R; Yuan, CM; Zhou, T1
Aisabor, AI; Davis, DA; Jaeger, HK; Shrestha, P; Stream, A; Yarchoan, R1
Gottwein, E; Manzano, M; Patil, A1
Chaudhary, PM; Gopalakrishnan, R; Matta, H; Tolani, B; Triche, T1

Other Studies

4 other study(ies) available for pomalidomide and Lymphoma, Primary Effusion

ArticleYear
Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease.
    Oncoimmunology, 2023, Volume: 12, Issue:1

    Topics: Antibodies, Monoclonal; Cytotoxicity, Immunologic; Humans; Lymphoma, Primary Effusion; Tretinoin

2023
Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
    PLoS pathogens, 2021, Volume: 17, Issue:1

    Topics: Angiogenesis Inhibitors; B7-2 Antigen; Gene Expression Regulation, Neoplastic; Humans; Intercellular Adhesion Molecule-1; Lymphoma, Primary Effusion; Signal Transduction; T-Lymphocytes; Thalidomide; Tumor Cells, Cultured

2021
CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
    Blood, 2018, 08-09, Volume: 132, Issue:6

    Topics: Casein Kinase Ialpha; Cell Line, Tumor; CRISPR-Cas Systems; Down-Regulation; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Ikaros Transcription Factor; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Lymphoma, Primary Effusion; Molecular Targeted Therapy; Neoplasm Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; Thalidomide; Ubiquitin-Protein Ligases

2018
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Oncogene, 2016, Apr-07, Volume: 35, Issue:14

    Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Gene Knockdown Techniques; Humans; Ikaros Transcription Factor; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Lymphoma, Primary Effusion; Mice; Nuclear Proteins; Peptide Hydrolases; Proto-Oncogene Proteins c-myc; Thalidomide; Transcription Factors; Triazoles; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays

2016